NCT05320939View on ClinicalTrials.gov

Immunological Basis for Mepolizumab Activity in COPD

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

May 31, 2025

Conditions
COPD
Interventions
DRUG

Mepolizumab 100 MG

30 subjects (≥ 300 eosinophils/ul) will receive mepolizumab 100 mg subcutaneously every 4 weeks for 5 complete doses.

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Temple University

OTHER

NCT05320939 - Immunological Basis for Mepolizumab Activity in COPD | Biotech Hunter | Biotech Hunter